Filing Flows › Comparisons › VCYT vs CDNA
Veracyte vs CareDx: VCYT and CDNA compared
Veracyte is the larger company: $152M of revenue in its latest quarter (Q3 2026) against $139M for CareDx (Q3 2026). CareDx is growing faster (+39% against +15% a year earlier). Veracyte is more profitable, with an operating margin of 10.9% against 5.8%.
Where the money goes: VCYT and CDNA
Veracyte (VCYT) · Q3 2026
Veracyte, Q3 2026: revenue $152M (+15% year over year), operating margin 10.9%, net earnings $31.5M, operating cash flow $40.3M. The chart follows the revenue to costs, profit and cash.
CareDx (CDNA) · Q3 2026
CareDx, Q3 2026: revenue $139M (+39% year over year), operating margin 5.8%, net earnings $19.3M, operating cash flow $12.7M. The chart follows the revenue to costs, profit and cash.
| Veracyte (VCYT) | CareDx (CDNA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $152M | $139M |
| Revenue growth, Y/Y | +15% | +39% |
| Gross margin | 70.6% | — |
| Operating margin | 10.9% | 5.8% |
| Net earnings | $31.5M | $19.3M |
| Net margin | 20.8% | 13.8% |
| Operating cash flow | $40.3M | $12.7M |
| Free cash flow | $37.9M | $11.1M |
| Market value | $3.7B | $3.5B |
| P/E | 32.4× | 26.6× |
| Analysts’ mean target | $57.40 | $93.50 |
Where the revenue comes from
Veracyte
- Testing revenue: $146M (96%)
- Product revenue: $4.6M (3%)
- Biopharmaceutical and other revenue: $709K (0%)
CareDx
- Testing services revenue: $119M (86%)
- Patient and digital solutions revenue: $20.2M (14%)
Questions
Which is bigger, Veracyte or CareDx?
Veracyte is the larger company: $152M of revenue in its latest quarter (Q3 2026) against $139M for CareDx (Q3 2026).
Is Veracyte or CareDx growing faster?
CareDx is growing faster (+39% against +15% a year earlier).
Which is more profitable, Veracyte or CareDx?
Veracyte is more profitable, with an operating margin of 10.9% against 5.8%.
More: Veracyte earnings · how Veracyte makes money · CareDx earnings · how CareDx makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.